Overview

Use of a Combined Regimen of Fluoxetine, Prednisolone and Ivermectin in the Treatment of Mild COVID-19 to Prevent Disease Progression Progression in Papua New Guinea

Status:
Not yet recruiting

Trial end date:
2022-07-30

Target enrollment:

Participant gender:

Summary

The Fluo-Pred-Iver clinical trial will test the efficacy of a combined regimen of Fluoxetine, Prednisolone and Ivermectin (Fluo-Pred-Iver), as treatment for ambulatory patients with mild COVID-19. The overarching idea of the work proposed herein is to investigate the use of Fluo-Pred-Iver to treat COVID-19, conducting a randomized controlled clinical trial to evaluate a new indication for these widely available drugs. It is estimated to include 954 participants.

Phase:

Phase 2/Phase 3

Details

Lead Sponsor:

Oriol Mitja

Collaborators:

Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia
National Department of Health, Papua New Guinea

Treatments:

Albendazole
Ascorbic Acid
Fluoxetine
Ivermectin
Prednisolone